• Bloomberg

  • SHARE

Eli Lilly & Co., the world’s biggest maker of psychiatric medicines, said Tuesday it expects revenue in Japan to increase 11 percent this year, spurred by sales of its antipsychotic drug, Zyprexa.

Revenue in Japan, the world’s second-biggest pharmaceutical market, may reach ¥100 billion in 2008, up from ¥89.8 billion last year, Newton Crenshaw, president of Eli Lilly’s Japanese unit, told reporters in Tokyo. Zyprexa will be the largest contributor, with sales in Japan expected to increase by at least 10 percent this year, he said.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW